Apoptosis induction and tumor cell repopulation: The yin and yang of radiotherapy

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Lauber, Kirsten ^a   Munoz, Luis E ^b   Berens, Christian ^b   Jendrossek, Verena ^c   Belka, Claus ^a   Herrmann, Martin ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIINFLAMMATORY AGENT; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CASPASE 3; CELECOXIB; CYTOKINE; LYSOPHOSPHATIDYLCHOLINE; NUCLEOTIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; VASCULAR TARGETING AGENT;

APOPTOSIS; AUTOPHAGY; BREAST CARCINOMA; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIVISION; CELL POPULATION; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CLONOGENESIS; COLORECTAL TUMOR; DISEASE CONTROL; DNA FRAGMENTATION; DOWNSTREAM PROCESSING; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NECROSIS; NONHUMAN; NOTE; PROTEIN EXPRESSION; RADIOSENSITIZATION; STROMA CELL; TREATMENT OUTCOME; TUMOR CELL; WOUND HEALING; ANIMAL; EDITORIAL; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; RADIATION EXPOSURE; RADIOTHERAPY;

ANIMALS; APOPTOSIS; CASPASE 3; HUMANS; MACROPHAGES; NEOPLASMS; RADIOTHERAPY;

EID: 83655203205     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-176     Document Type: Note

References (32)

1. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O'Sullivan B, He Z, Peng Y, Tan AC, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011, 17(7):860-866. 10.1038/nm.2385, 21725296.
2. Connell PP, Weichselbaum RR. A downside to apoptosis in cancer therapy?. Nat Med 2011, 17(7):780-782. 10.1038/nm0711-780, 21738153.
3. Itani W, Geara F, Haykal J, Haddadin M, Gali-Muhtasib H. Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells. Radiat Oncol 2007, 2:1. 10.1186/1748-717X-2-1, 1770925, 17201910.
4. Liao X, Che X, Zhao W, Zhang D, Long H, Chaudhary P, Li H. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol 2010, 5:98. 10.1186/1748-717X-5-98, 2974742, 20977754.
5. Rubel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 2006, 1:6. 10.1186/1748-717X-1-6, 1475859, 16722524.
6. Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol 2010, 5:108. 10.1186/1748-717X-5-108, 2998511, 21080918.
7. Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009, 4:69. 10.1186/1748-717X-4-69, 2806296, 20028557.
8. Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, Bartelink H, Rooswinkel R, Lafleur V, Verheij M. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol 2009, 4:47. 10.1186/1748-717X-4-47, 2771029, 19852810.
9. Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 2009, 75(1):198-202. 10.1016/j.ijrobp.2009.04.038, 19695436.
10. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, Daniel PT, Jendrossek V, Budach W, Belka C. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006, 25(37):5145-5154.
11. Marini P, Junginger D, Stickl S, Budach W, Niyazi M, Belka C. Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions. Radiat Oncol 2009, 4:49. 10.1186/1748-717X-4-49, 2772841, 19860913.
12. Marini P, Jendrossek V, Durand E, Gruber C, Budach W, Belka C. Molecular requirements for the combined effects of TRAIL and ionising radiation. Radiother Oncol 2003, 68(2):189-198. 10.1016/S0167-8140(03)00186-5, 12972315.
13. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101(4):890-898. 10.1172/JCI1112, 508637, 9466984.
14. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390(6658):350-351. 10.1038/37022, 9389474.
15. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8(12):958-969. 10.1038/nri2448, 2724991, 19029990.
16. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461(7261):282-286. 10.1038/nature08296, 2851546, 19741708.
17. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113(6):717-730. 10.1016/S0092-8674(03)00422-7, 12809603.
18. Mueller RB, Sheriff A, Gaipl US, Wesselborg S, Lauber K. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. Autoimmunity 2007, 40(4):342-344. 10.1080/08916930701356911, 17516225.
19. Peter C, Waibel M, Radu CG, Yang LV, Witte ON, Schulze-Osthoff K, Wesselborg S, Lauber K. Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A. J Biol Chem 2008, 283(9):5296-5305.
20. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002, 109(1):41-50. 150814, 11781349.
21. Stadler K, Frey B, Munoz LE, Finzel S, Rech J, Fietkau R, Herrmann M, Hueber A, Gaipl US. Photopheresis with UV-A light and 8-methoxypsoralen leads to cell death and to release of blebs with anti-inflammatory phenotype in activated and non-activated lymphocytes. Biochem Biophys Res Commun 2009, 386(1):71-76. 10.1016/j.bbrc.2009.05.130, 19501044.
22. Nagata S. DNA degradation in development and programmed cell death. Annu Rev Immunol 2005, 23:853-875. 10.1146/annurev.immunol.23.021704.115811, 15771588.
23. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001, 3(4):339-345. 10.1038/35070009, 11283606.
24. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001, 3(4):346-352. 10.1038/35070019, 11283607.
25. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391(6662):43-50. 10.1038/34112, 9422506.
26. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998, 391(6662):96-99. 10.1038/34214, 9422513.
27. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998, 273(16):9357-9360. 10.1074/jbc.273.16.9357, 9545256.
28. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006, 94(3):346-350. 10.1038/sj.bjc.6602942, 2361146, 16421592.
29. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11):1071-1080. 10.1056/NEJMoa050405, 15713944.
30. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2011,
31. Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. Clin Lung Cancer 2011, 12(2):125-130. 10.1016/j.cllc.2011.03.007, 21550559.
32. De Ruysscher D, Bussink J, Rodrigus P, Kessels A, Dirx M, Houben R, Wanders R. Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial. Radiother Oncol 2007, 84(1):23-25. 10.1016/j.radonc.2007.05.008, 17532073.